

# CURRICULUM VITAE

<b>Name</b>	Emilie Le Rhun, MD, PhD
<b>Date of birth</b>	27.12.1975
<b>Place of birth</b>	Quimper, France
<b>Citizenship</b>	French
<b>Current position</b>	Departments of Neurosurgery, University Hospital and University of Zurich, Frauenklinikstrasse 10, CH-8091 Zurich, Switzerland, Telephone neurology +41 44 2555500/ neurosurgery+41 44 255 29 92, E-mail: emilie.lerhun@usz.ch
<b>French physician number</b>	Ordre des médecins (ADELI) – France: 59-18277 RPPS: 10002306545

## Education and Employment

From June 2020	Senior Specialist Departments of Neurosurgery, University Hospital and University of Zurich, Frauenklinikstrasse 10, CH-8091 Zurich, Switzerland
November 1st, 2017- April 22, 2020	Senior specialist Department of Neurosurgery, Neuro-oncology unit, Lille University Hospital (CHU de Lille), Lille, France; with assignment to the Breast Unit of the Oscar Lambret Cancer Center, Lille, France  Visiting Scientist, Laboratory of Molecular Neuro-oncology, Department of Neurology, University Hospital, Zurich, Switzerland
2016 –2017	Academic mobility Laboratory of Molecular Neuro-oncology, Department of Neurology, University Hospital, Zurich, Switzerland (November 2016-April 2017 & August 2017-October 2017)  Brain Tumor Clinic, Princess Margaret Cancer Center, Toronto, Canada (May 2017-July 2017)
2007-2016	Senior Specialist Lille University Hospital (CHRU de Lille), Lille, France, with assignments to - Neuro-oncology, Neurosurgery Department, Lille University Hospital, France (2007-2016) - Breast Unit of the Oscar Lambret Cancer Center, Lille, France (2007-2016) - Neuro-oncology, Neurology Department, Valenciennes General Hospital, Valenciennes, France (2007-2016) - Neurology, Lille University Hospital, France (2007-2011) - Clinical Research Department, Oncology Federation, Lille University Hospital, France (2010-2011) - Oncology Federation at Lille University Hospital, France (2007-2010)

2006 - 2007	Fellowship and 2 <sup>nd</sup> year of the Advanced specialized 2 years in Oncology (Diplôme d'Etudes Spécialisées Complémentaires de <i>Cancérologie</i> : DESC) Department of Radiotherapy (Radiotherapy – Oscar Lambret Cancer Center, Lille) and Lille University, Lille, France
2005 - 2006	Fellowship and 1 <sup>st</sup> year of the Advanced specialized 2 years in Oncology (Diplôme d'Etudes Spécialisées Complémentaires de <i>Cancérologie</i> : DESC) Department of Medical Oncology (Breast cancer unit – Oscar Lambret Cancer Center, Lille) and Lille University, Lille, France
2003 - 2005	Fellowship Department of Neurology (Neurology and movement disorders - CHRU de Lille, University Hospital) and Lille University, Lille, France
1999 - 2003	Neurology Residency (10 rotations) Lille University, Lille, France
1994 -1999	Medical School Bretagne Occidental University – Brest University - Faculty of Medicine and Medical Sciences, Brest, France

### **Qualifications and licenses**

October 26 <sup>th</sup> , 2007	French board certification in neuro-oncology
October 31 <sup>th</sup> , 2003	French board certification in neurology
November 1 <sup>st</sup> , 2003	Licensed physician in France

### **Degrees**

April 2017	PhD in Neurobiology; Lille university - Faculty of Medicine
June 2008	Inter-University Diploma in Neuro-Oncology; Nice-Sophia Antipolis University
October 2007	Advanced specialized medical diploma in Oncology (post-graduate degree); Lille University – Faculty of Medicine
October 2003	Specialized medical degree in Neurology; Lille University - Faculty of Medicine
September 2003	Medical degree, state certified diploma, Lille University - Faculty of Medicine
October 2002	Inter-University Diploma in Neurophysiology; Lille University

## Science

- June 2020 **Scientist at the Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland**
- 2016-June 2020 Visiting scientist at the Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
- 2014-ongoing PhD in Neurobiology, Neurosciences  
Member of the unit PRISM INSERM U1192  
  
Laboratory: Protéomique, réponse inflammatoire et spectrométrie de Masse (PRISM). INSERM U1192. Lille University, Villeneuve d'Ascq, France
- 2006-2007 Master's degree in Neurosciences.  
main option: physiology, physiopathology and pharmacology of integrated systems and neurosciences, Lille University, France  
  
Laboratory: National Center of Scientific Research (Centre National de la Recherche Scientifique) (CNRS) – UMR 8161, Institut Fédératif de Recherche (IFR) 142, Institute of Biology of Lille, Pasteur Institute of Lille, Lille University, Lille, France
- February 07, 2000 License bachelor – Brest, Bretagne Occidental University  
- maîtrise de sciences biologiques et médicales  
- certificat c1 de biochimie générale (general biochemistry) (Brest University Hospital, France)  
- certificat c2 de radio-anatomie et imagerie sectionnelle (radio-anatomy and sectional imaging) (Brest University Hospital, France)

## Scientific publications

- Original articles: 81  
Reviews, guidelines: 62  
Book chapters: 11
- 10 Major scientific publications
1. Le Rhun E, Wallet J, Mailliez A, Le Deley MC, Rodrigues I, Boulanger T, Lorgis V, Barrière J, Robin YM, Weller M, Bonnetterre J. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. *Neuro Oncol.* 2020 Apr 15;22(4):524-538.
  2. Le Rhun E, Devos P, Houillier C, Cartalat S, Chinot O, Di Stefano AL, Lepage C, Reyns N, François Dubois F, Weller M. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial. *Neurology* 2019 Nov 5;93(19):e1799-e1806.
  3. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklerhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, van den Bent M, Wen PY, Bendzus M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee. The RANO

- Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal. 2019 May 6;21(5):648-658.
4. Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, Weller M. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. *Int J Cancer*. 2019 Jul 1;145(1):242-253.
  5. Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. *Eur J Cancer* 2018 Sept;101:95-104.
  6. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfopoulos V, Bromberg JC, Platten M, Klein M, Van den Bent MJ. Lomustine and bevacizumab in progressive glioblastoma. *N Engl J Med*. 2017 Nov 16;377(20):1954-1963.
  7. Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonnetterre J. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. *Eur J Cancer*. 2017 Dec;87:189-198.
  8. Le Rhun E, Duhamel M, Wisztorski M, Gimeno JP, Zairi F, Escande F, Reyens N, Kobeissy F, Maurage CA, Salzet M, Fournier I. Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. *Biochim Biophys Acta*. 2017 Jul;1865(7):875-890.
  9. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M; EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. *Ann Oncol*. 2017 Jul 1;28(suppl\_4):iv84-iv99.
  10. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffiatti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. Evidence-based management of adult patients with diffuse glioma. *Lancet Oncol*. 2017 Jun;18(6):e315-e329.

## Memberships

- European Organization For Research And Treatment Of Cancer (EORTC)
  - Brain Tumor Group: Member of the Steering Committee, Young neuro-oncologist 2015-2018, Chair of the CNS metastases committee from October 2016
  - Elderly Task Force from 2016
    - Enrolment in the Early Career Investigators/leadership program from 2017-2019
- EANO (European Association of Neuro-Oncology)
  - Member of the Scientific Committee from October 2016
  - Member of the Guidelines Committee from May 2019
  - Member of EANO Guideline Task Force on Glioma
  - Member of EANO Guideline Task Force on Brain Metastases
  - Member of EANO Guideline Task Force on Palliative Care

- Coordinator of the Women in Neuro-Oncology task force /Disparity Committee since its creation in 2019
- ESMO (European Society for Medical Oncology)
- Scientific Committee ESMO Annual Meeting Madrid 2017, Munich 2018, Barcelona 2019
- ESMO Educational Committee (CNS Faculty coordinator 2017-2020)
- SNO (Society for Neuro-Oncology)
- RANO (Response Assessment In Neuro-Oncology) Working Group, Subgroup RANO/LMD (Leptomeningeal Disease) also named LANO (RANO In Lepto-Meningeal Metastases) and RANO-PRO (Patient Reported Outcome)
- ASCO (American Society of Clinical Oncology)
- Swiss Neuro-oncology Society
- ANOCEF (French-Speaking Neuro-Oncologists Association - Association Des Neuro-Oncologues D'expression Française)
- Member of the administrative council
- Coordinator of the CNS (brain metastases and leptomeningeal metastases) network
- Coordinator of the cognition, QOL (Quality of Life) and supportive care network
- Liaison with the EORTC
- NENO (French North East Neuro-oncology Network - Nord Est Neuro-Oncologie) (President from 2015 - 2017)
- SIOG (International Society of Geriatric Oncology) (since 2019)

**Ad hoc reviewer**

Annals of Oncology, Breast cancer research and treatment, Cancer, Cancer letters, European Journal of Cancer, ESMO Open, International Journal of Cancer, Journal of Clinical Oncology, Journal of Neuro-Oncology, Lancet Oncology, Lung Cancer, Neurology, Neuro-Oncology, Neuro-Oncology Advances, Neuro-Oncology Practice, The Oncologist

**Editorial Board**

Neuro-oncology since 2015  
 ESMO Open since 2018  
 Journal of Neuro-Oncology since 2018

**Main trials as a coordinator**

Principle investigator

DEPOSEIN: Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: the randomised, open-label phase III DEPO-SEIN trial (NCT01645839)

PLATUM: Secondary prophylaxis of temozolomide-induced thrombocytopenia in glioblastoma (NCT02227576)

EORTC 1608: STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study (STEAM) (NCT032241041)

Coordinator for France

EORTC Study 1709-BTG: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard

temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma (NCT03345095)

EORTC 1419 / BTFC: Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma (NCT03770468)

EORTC 1308: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (The ROAM trial)

EORTC 1320: Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (NCT02234050)

**Training on ICH/  
GCP**

Last Good Clinical Practice Guidelines Course: September 11, 2019